(Reuters) - AstraZeneca forecast a likely slowdown in revenue growth this year, assuming a hit from China's coronavirus epidemic lasting up to a few months, although it added there had been limited disruption to its operations so far. Shares in the company, one of the world's major drugmakers, tumbled as much as 6% in early Friday trade after fourth-quarter results also missed analysts' expectations. However, they recovered after CEO Pascal Soriot played down the impact of the coronavirus outbreak on the business so far. The company, moving into a third year of growth, predicted revenues would rise by a high single-digit to a low double-digit percentage at constant exchange rates this year, compared with 13% in 2019. "New drugs which were growth drivers all through 2019 posted below-expectations fourth-quarter sales," Berrigaud said. AstraZeneca forecast core earnings per share would rise by a mid- to high-teens percentage in 2020, compared with just 1% in 2019 and analysts' current consensus forecast of about 20%. Soriot also said the company was on track to reach an operating profit margin target of more than 30% in 2021.
3 other references
Latest Stories From Referenced Companies
Feb 21, 2020
Biggest Innovations in Gynecological Cancer Drugs Market Emerging Trends and Forecast by Leading Players Eli Lilly and Company, GlaxoSmithKline, Merck, Novartis - Chronicle 99
Feb 20, 2020